Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Tarsus Pharmaceuticals Inc shares valued at $1,255,684 were sold by Whitfield Dianne C. on Jan 02 ’26. At $80.67 per share, Whitfield Dianne C. sold 15,565 shares. The insider’s holdings dropped to 23,393 shares worth approximately $1.83 million following the completion of this transaction.
Also, Whitfield Dianne C. purchased 15,565 shares, netting a total of over 1,266,680 in proceeds.
Before that, Azamian Bobak R. had sold 6,000 shares from its account. In a trade valued at $495,089, the President/CEO and Board Chair traded Tarsus Pharmaceuticals Inc shares for $82.51 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $66.99 million.
As published in their initiating research note from Barclays on December 09, 2025, Tarsus Pharmaceuticals Inc [TARS] has been an Overweight and the price target has been revised to $100. Analysts at Mizuho started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November.
Analyzing TARS Stock Performance
On last trading session, Tarsus Pharmaceuticals Inc [NASDAQ: TARS] plunged -2.25% to $78.08. The stock’s lowest price that day was $76.92, but it reached a high of $81.57 in the same session. During the last five days, there has been a drop of approximately -5.16%. Over the course of the year, Tarsus Pharmaceuticals Inc shares have jumped approximately 40.26%. Shares of the company reached a 52-week high of $83.92 on 01/02/26 and a 52-week low of $76.34 on 01/05/26.
Support And Resistance Levels for Tarsus Pharmaceuticals Inc (TARS)
According to the 24-hour chart, there is a support level at 76.13, which, if violated, would cause prices to drop to 74.17. In the upper region, resistance lies at 80.82. The next price resistance is at 83.55. RSI (Relative Strength Index) is 43.71 on the 14-day chart, showing neutral technical sentiment.
Is Tarsus Pharmaceuticals Inc subject to short interest?
Stocks of Tarsus Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.36 million shares to 6.81 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 7.17 million shares. A decline of -5.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 15.41 of the overall float, the days-to-cover ratio (short ratio) decline to 15.41.
Which companies own the most shares of Tarsus Pharmaceuticals Inc (TARS)?
In terms of Tarsus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 94 in the next 12 months, up nearly 17.68% from the previous closing price of $79.88. Analysts anticipate Tarsus Pharmaceuticals Inc stock to reach 100 by 2026, with the lowest price target being 51. In spite of this, 4 analysts ranked Tarsus Pharmaceuticals Inc stock as Buy at the end of 2026. On November 20, 2023, Goldman assigned a price target of “a Neutral” to the stock and initiated coverage with a $19.
